Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zinpentraxin alfa (PRM-151) long-term extension in IPF
NCT04594707Phase 3Terminated
- Sponsor
- Roche
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 28
01
Overview
A Phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Started Aug 2021; status: terminated.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04594707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04594707.